Skip to main content

Werewolf Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 7, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 7, 2026

HOWL$0.97-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets as of and

Condensed Consolidated Balance Sheets (unaudited)

(amounts in thousands, except share and per share amounts)

March 31,2026December 31,2025
Assets
Current assets:
Cash and cash equivalents$46,450$57,050
Prepaid expenses and other current assets2,2841,536
Total current assets48,73458,586
Property and equipment, net4,2904,688
Restricted cash and cash equivalents, net of current portion—901
Operating lease right of use asset4,9985,216
Other assets—5
Total assets$58,022$69,396
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$3,569$754
Accrued expenses and other current liabilities4,5155,407
Operating lease liability, current1,6041,751
Note payable, net of discount and issuance costs28,83128,236
Total current liabilities38,51936,148
Operating lease liability, net of current portion7,2167,684
Derivative liability85759
Total liabilities45,82044,591
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued or outstanding as of March 31, 2026 and December 31, 2025——
Common stock, $0.0001 par value, 200,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 48,596,817 shares issued and outstanding as of March 31, 2026 and December 31, 202555
Additional paid-in capital501,139500,210
Accumulated deficit(488,942)(475,410)
Total stockholders’ equity12,20224,805
Total liabilities and stockholders’ equity$58,022$69,396
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.